Welcome to LookChem.com Sign In|Join Free

Hubei Moxin Biotechnology Co., Ltd

Diamond Supplier Enterprise Certification

Diamond
Supplier
1st
years
Home>>Products>>Orlistat;96829-58-2

Products Categories

Product Certification&
Enterprise Certification

More Detail

Hubei Moxin Biotechnology Co., Ltd

Country: China (Mainland)

Business Type:Lab/Research institutions

Ms.Du

Tel: +86-173-20513646

Mobile: 17320513646

Tel: +86-173-20513646

Fax:

URL: http://www.molcoo.com

Province/state: Hu Bei

City: Wuhan

Street: Company address: Room 005, 15th Floor, Building D2, Phase III, Software New Town, No. 8 Huacheng Avenue, East Lake High-tech Development Zone, Wuhan, Hubei Province, China

MaxCard:


qq Contact Suppliers

Orlistat;96829-58-2

CAS NO.96829-58-2

  • FOB Price: USD: 10.00-10.00 /Milligram Get Latest Price
  • Min.Order: 10 Milligram
  • Payment Terms: T/T
  • Available Specifications:

    1(10.0-10000)Milligram

Contact Supplier

Product Details

Keywords

  • Orlistat
  • 96829-58-2
  • C29H53NO5

Quick Details

  • ProName: Orlistat;96829-58-2
  • CasNo: 96829-58-2
  • Molecular Formula: C29H53NO5
  • Appearance: White to off white powder
  • Application: experiment research
  • DeliveryTime: prompt delivery
  • PackAge: Food bags, aluminum foil bags
  • Port: Shenzhen/hongkong
  • ProductionCapacity: 5000 Gram/Year
  • Purity: 99%+ HPLC
  • Storage: cool and dry
  • Transportation: DHL,EMS,TNT,UPS,EMS,by air,by sea;
  • LimitNum: 10 Milligram
  • Moisture Content: 0.1%
  • Impurity: 0.1%

Superiority

We supply over 20000 types of spot impurity reference materials, with sufficient supply and same day delivery to meet customers' urgent needs for replenishment at any time. The company has its own research and development center and laboratory, and the team members have over ten years of experience in developing drug impurity reference standards. Our website www.molcoo.com covers over 98% of cutting-edge generic drug projects, with complete structural formulas that greatly save customers time in impurity structure analysis and inference. All products undergo strict quality control testing and provide relevant information such as COA, H-NMR, C-NMR, MS/GC-MS, HPLC/GC purity, QNMR quantification, TGA thermogravimetric analysis, IR infrared, UV ultraviolet, two-dimensional (COSY, NOESY, HMBC, HMQC), etc. These structural confirmation spectra ensure quality and reliability. Our products have a wide range of categories, fast delivery time, good quality, and low prices, which can quickly solve various customer needs such as replenishment and consistency evaluation.

Details

WhatsAPP: +86 17320513646                      E-mail: anna@molcoo.com

 

  • Product Code:O020000
  • English Name:Orlistat
  • English Alias:(S)-(S)-1-((2S,3S)-3-hexyl-4-oxooxetan-2-yl)tridecan-2-yl 2-formamido-4-methylpentanoate
  • CAS No.:96829-58-2
  • Molecular Formula:CHNO
  • Molecular Weight:495.73

Advantages

  • Pharmaceutical-Grade Purity:Complies with USP, EP pharmacopoeia standards, HPLC purity ≥99.0%, suitable for oral formulation raw material requirements.
  • Stability Profile:Shelf life of 36 months under 2-8℃ light-protected storage; melting point ~50-52℃, prone to ester bond hydrolysis at high temperatures, requiring production environment temperature control.

Applications

  • Obesity Treatment:As a gastrointestinal lipase inhibitor, it reduces dietary fat absorption by 30% via pancreatic lipase inhibition, clinically used for obese patients with BMI ≥30 or BMI ≥27 with comorbidities.
  • Formulation Development:Available in oral dosage forms (capsules, tablets), often combined with low-calorie diets; co-administration with vitamins A, D, E, K is recommended to prevent fat-soluble vitamin deficiency.

Background Description

Orlistat is the first non-central obesity treatment drug approved by FDA, developed by Roche and launched in 1999. Its mechanism relies on selective inhibition of gastrointestinal lipases without entering the bloodstream, leading to minimal systemic adverse reactions. With rising global obesity rates, Orlistat has become a WHO-recommended first-line weight loss drug, marketed as an over-the-counter medication in multiple countries since 2010.

Research Status

  • Dosage Form Optimization:Novel microencapsulated formulations reduce gastrointestinal discomfort (e.g., diarrhea, oily stools) and increase bioavailability by 15%; topical fat-reducing gels are in Phase II clinical trials for local adipose tissue treatment.
  • Combination Therapy:Phase III trials of Orlistat + GLP-1 receptor agonists (e.g., semaglutide) show 22% greater weight loss than monotherapy, but hepatobiliary function monitoring is required.
  • Safety Research:Long-term use (≥5 years) may increase gallstone risk (incidence ~5-8%), with FDA-mandated labeling warnings; recent studies suggest its modulation of gut microbiota may affect weight loss efficacy.

WhatsAPP: +86 17320513646
E-mail: anna@molcoo.com

 

NEW IN STOCK!

The Molcoo Laboratory added drug impurity reference standardsincluding Baricitinib, Piperazine, Benzylpenicillin, Tranilast and multiple N-Nitroso drug impurities! Now available for immediate delivery!